Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Abstract Background Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for “repurposing” as anti-viral a...

Full description

Bibliographic Details
Main Authors: Hari Krishna Ananthula, Scott Parker, Erin Touchette, R. Mark Buller, Gopi Patel, Daniel Kalman, Johanna S. Salzer, Nadia Gallardo-Romero, Victoria Olson, Inger K. Damon, Tessa Moir-Savitz, Larry Sallans, Milton H. Werner, Catherine M. Sherwin, Pankaj B. Desai
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Pharmacology and Toxicology
Subjects:
Tyrosine kinase inhibitor
Pharmacokinetics
Allometry
Animal rule
Online Access:http://link.springer.com/article/10.1186/s40360-018-0270-x

Internet

http://link.springer.com/article/10.1186/s40360-018-0270-x

Similar Items